Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.71 |
| ▸ | MTOR | P42345 | 9/20 | 0.71 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754485 | 0.88 | MTOR (0.54) | PIK3CAMTORPIK3CDPIK3CGKCNH2 | |
| SCHEMBL11030188 | 0.83 | MTOR (1.00) | PIK3CAMTORADORA2AADORA1 | |
| SCHEMBL2787610 | 0.80 | MTOR (1.00) | PIK3CAMTORADORA2ACYP3A4ADORA1 | |
| SCHEMBL11029859 | 0.79 | MTOR (0.74) | PIK3CAMTOR | |
| SCHEMBL2786709 | 0.78 | MTOR (0.65) | PIK3CAMTORADORA2A | |
| SCHEMBL756258 | 0.76 | MTOR (0.65) | PIK3CAMTORPIK3CGKCNH2ADORA2A | |
| SCHEMBL753664 | 0.75 | MTOR (0.74) | PIK3CAMTORADORA2ACYP3A4ADORA1 | |
| SCHEMBL16161627 | 0.75 | MTOR (0.65) | PIK3CAMTORADORA2ACYP3A4ADORA1 | |
| SCHEMBL13188530 | 0.74 | PIK3CG (0.62) | PIK3CAMTORPIK3CDPIK3CGKCNH2 | |
| SCHEMBL751893 | 0.74 | MTOR (0.47) | PIK3CAMTORKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | claimed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | claimed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | claimed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | claimed |
| EP-2430013-B1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC (US) | 2014-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | PIK3CA 1/4885MTOR 21/4885PIK3CD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.